Skip to content
Companies

Vira Regen

Electrical bone growth stimulator for fracture repair

Raised to date

No sales reported yet

of $3M offered across 1 Form D filing

Still open
$3M
Last filed
Mar 23, 2026

About

Vira Regen Inc. is a Salt Lake City biotech developing gene-specific bioelectronic medicines — noninvasive electroceuticals that use electrical stimulation to switch on the body's own regenerative genetic pathways. The company uses computational biology and custom machine learning to target specific genetic pathways on demand rather than applying undifferentiated stimulation. Its lead program is a bone growth stimulator for accelerated fracture repair, developed with roughly $2 million in nondilutive U.S. Department of Defense funding awarded through MTEC for military and civilian applications. The company is pursuing a Breakthrough Device Designation for its gene-targeted stimulation approach.

Gene-specific rather than general electrical stimulation: computational biology and machine learning are used to control which genetic pathways the device activates, aiming at targeted tissue regeneration through a noninvasive device rather than a drug.

Funding

  • EquityFiled Mar 23, 2026Form D
    None sold/ $3M

Product

Gene-targeted bone growth stimulator

Bioelectronic medical device

A noninvasive electroceutical device that applies gene-specific bioelectric stimulation to accelerate bone regeneration in traumatic fractures and orthopedic recovery. It is the company's lead program, developed with Department of Defense support, and is being advanced toward a Breakthrough Device Designation.

  • Noninvasive electrical stimulation
  • Gene-specific pathway targeting rather than undifferentiated stimulation
  • Computational biology and custom machine learning to control which pathways activate

Built for

Orthopedic and trauma care providers, plus military medicine — patients with bone fractures, nonunions and musculoskeletal injuries

People on file